NCT05481307View on ClinicalTrials.gov

A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 2, 2022

Primary Completion Date

October 25, 2022

Study Completion Date

October 25, 2022

Conditions
Healthy
Interventions
DRUG

RLD2202

Take it once a day per period

DRUG

RLD2203

Take it once a day per period

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT05481307 - A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203 | Biotech Hunter | Biotech Hunter